⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606601 | 1.00 | — | — | |
| SCHEMBL30606528 | 0.82 | CFD (0.37) | — | |
| SCHEMBL26599069 | 0.82 | CFD (0.37) | — | |
| SCHEMBL26599045 | 0.78 | ADRB2 (0.33) | — | |
| SCHEMBL30606590 | 0.78 | ADRB2 (0.33) | — | |
| SCHEMBL31174638 | 0.78 | GAA (0.40) | — | |
| SCHEMBL26598995 | 0.78 | GAA (0.40) | — | |
| SCHEMBL31500335 | 0.76 | DRD2 (0.32) | — | |
| SCHEMBL26599194 | 0.76 | DRD2 (0.32) | — | |
| SCHEMBL30606498 | 0.71 | CFD (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4511355-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FundaMental Pharma GmbH (DE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024223617-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |